ImExHS Limited (IME) Fair Value & Analysis
Healthcare · AU · Market cap A$19.0M
Fair value as of: Jun 24, 2026
Analysis
ImExHS Limited (IME) currently trades at A$0.3500, while our model-based Fair Value estimate is A$0.4100 — implying the stock looks roughly 17.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. The company operates in two segments: Software and Radiology. It offers medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system. The company's solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; and ANTEROS, a cardiology software solution. It also provides radiological diagnostic services to hospitals and medical facilities; medical images and radiologists' interpretation; reports to develop artificial intelligence (AI) tools; and outsourced radiology services, as well as teleradiology services. ImExHS Limited was incorporated in 2001 and is based in Sydney, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is ImExHS Limited (IME) undervalued?
What is the fair value of IME?
What is the quality score of IME?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.